Tarsus Pharmaceuticals (NASDAQ: TARS) announced it has dosed the first participant in a phase 2 clinical trial evaluating TP-05, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE